Breaking Finance News

Zacks Investment Research downgraded Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to Sell in a report released today.

Zacks Investment Research has downgraded Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to Sell in a report released on 6/21/2017.

Just yesterday Enanta Pharmaceuticals Inc (NASDAQ:ENTA) traded 1.72% higher at $35.34. Enanta Pharmaceuticals Inc’s 50-day moving average is $40.21 and its 200-day moving average is $34.12. The last stock price is up 26.37% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. 113,030 shares of ENTA traded hands, down from an average trading volume of 214,512

Recent Performance Chart

Enanta Pharmaceuticals Inc (NASDAQ:ENTA)

Enanta Pharmaceuticals Inc has 52 week low of $22.17 and a 52 week high of $45.14 and has a market capitalization of $0.

Brief Synopsis On Enanta Pharmaceuticals Inc (NASDAQ:ENTA)

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *